Specific IDH1 and IDH2 mutations are characteristic of distinct subtypes, including low‐grade gliomas, secondary GBMs, chondrosarcomas, intrahepatic cholangiocarcinomas, and certain hematologic cancers.56 Here, IDH2 is linked to central nervous system cancer.